KYNTRA BIO Stock Price, News & Analysis
Company Description
Kyntra Bio, Inc. is a biopharmaceutical company that develops therapies for oncology and rare disease indications. The company, formerly known as FibroGen, trades on Nasdaq under the symbol KYNB and is headquartered in San Francisco, California. Its disclosed programs center on roxadustat for anemia-related indications and FG-3246, an antibody-drug conjugate program for metastatic castration-resistant prostate cancer.
Kyntra Bio's pipeline includes roxadustat, marketed in some countries as 爱瑞卓® and EVRENZO™, which is approved in Europe, Japan, China and numerous other countries for the treatment of anemia in chronic kidney disease patients on dialysis and not on dialysis. The company continues to evaluate development of roxadustat in the United States for anemia associated with lower-risk myelodysplastic syndromes, or LR-MDS. This program places Kyntra Bio within the hematology and rare disease areas of drug development while building on an approved molecule outside the United States for CKD anemia.
The company's oncology program is built around FG-3246, also known as FOR46, a first-in-class antibody-drug conjugate targeting CD46. FG-3246 is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer, or mCRPC. Kyntra Bio also reports an associated biomarker program, FG-3180, a CD46-targeted PET imaging agent intended to support the FG-3246 development program.
Kyntra Bio's operating model is that of a clinical-stage and development-focused biotechnology company. Its recurring activities include clinical development, regulatory interactions, data presentations at medical conferences, and financial reporting tied to research and development spending. The company's public disclosures also reflect its transition from the former FibroGen identity to Kyntra Bio and its focus on a narrower set of oncology and rare disease assets.
As a public biotechnology issuer, Kyntra Bio's corporate record includes updates on pipeline development, quarterly and annual financial results, proxy governance matters, equity compensation, and Nasdaq listing compliance. These disclosures document both the scientific focus of its drug candidates and the capital, governance, and reporting requirements associated with a development-stage public biopharmaceutical company.
Stock Performance
KYNTRA BIO (KYNB) stock last traded at $6.90, down 1.25% from the previous close. Over the past 12 months, the stock has lost 27.4%. At a market capitalization of $28.4M, KYNB is classified as a micro-cap stock with approximately 4.0M shares outstanding.
KYNB Rankings
Latest News
KYNTRA BIO has 7 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, earnings date, conferences. View all KYNB news →
SEC Filings
KYNTRA BIO has filed 10 recent SEC filings, including 2 Form 4, 2 Form 4/A, 2 Form SCHEDULE 13G/A, 2 Form 10-Q. The most recent filing was submitted on May 19, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all KYNB SEC filings →
Insider Radar
Insider buying activity at KYNTRA BIO over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
KYNTRA BIO generated $6.4M in revenue over the trailing twelve months, retaining a 91.4% gross margin, operating income reached -$45.9M (-712.7% operating margin), and net income was $183.5M, reflecting a 2848.6% net profit margin. Diluted earnings per share stood at $45.37. The company generated -$4.8M in operating cash flow. With a current ratio of 3.39, the balance sheet reflects a strong liquidity position.
Upcoming Events
Phase 2 interim analysis
Phase 2 monotherapy interim analysis
Roxadustat Phase 3 start
FG-3246 interim analysis
KYNTRA BIO has 4 upcoming scheduled events. The next event, "Phase 2 interim analysis", is scheduled for July 1, 2026 (in 30 days). Investors can track these dates to stay informed about potential catalysts that may affect the KYNB stock price.
Short Interest History
Short interest in KYNTRA BIO (KYNB) currently stands at 112.8 thousand shares, down 0.9% from the previous reporting period, representing 2.8% of the float. This relatively low short interest suggests limited bearish sentiment. The 7.0 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for KYNTRA BIO (KYNB) currently stands at 7.0 days, up 139.7% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has increased 31.9% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 2.9 to 7.0 days.
KYNB Company Profile & Sector Positioning
KYNTRA BIO (KYNB) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.